Ramón García-Gómez

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt et al. · JAMA Oncology · 2015 · 238 citations · Full text

Medicine, Molecular Biology, Oncology +17

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

Pilar Garrido, Rafael Rosell, Antonio Arellano et al. · Lung Cancer · 2013 · 27 citations

Medicine, Oncology, Chemotherapy +15

Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients with Cisplatin/Gemcitabine–Treated Stage IV Non–Small-Cell Lung Cancer

Vicente Alberola, Carme Sarries, Rafael Rosell et al. · Clinical Lung Cancer · 2004 · 19 citations

Medicine, Genetics, Oncology +12

Phase II study of mitonafide in non-small cell lung cancer (NSCLC)

Antonio Casado, Rafael Rosell, Ramón García-Gómez et al. · Investigational New Drugs · 1996 · 18 citations

Medicine, Oncology, Pharmacology +12